PE20091092A1 - HETEROCYCLIC COMPOUNDS AS INHIBITORS OF THE HEDGEHOG PATH - Google Patents

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF THE HEDGEHOG PATH

Info

Publication number
PE20091092A1
PE20091092A1 PE2008001563A PE2008001563A PE20091092A1 PE 20091092 A1 PE20091092 A1 PE 20091092A1 PE 2008001563 A PE2008001563 A PE 2008001563A PE 2008001563 A PE2008001563 A PE 2008001563A PE 20091092 A1 PE20091092 A1 PE 20091092A1
Authority
PE
Peru
Prior art keywords
methyl
inhibitors
carboxamide
pyridin
trifluoromethyl
Prior art date
Application number
PE2008001563A
Other languages
Spanish (es)
Inventor
Benjamin Fauber
Alexander Hird
James Janetka
Daniel John Russell
Bin Yang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20091092A1 publication Critical patent/PE20091092A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO HETEROCICLICO DE FORMULA (I), DONDE R1, R2 Y R3 SON H, HALOGENO O ALQUILO C1-C6; R4 ES HALOGENO, ALQUILO C1-C6 O HALOALQUILO C1-C6; W ES N, O, S, CR5, ENTRE OTROS; R5 ES H, ALCOXILO C1-C6, ALQUILO C1-C6, ENTRE OTROS; A ES N, CR6, NR6, N, O, S; R6 ES H, ALCOXILO C1-C6, AMINO, AMIDO, ENTRE OTROS; q Y p SON 0 O 1. SON COMPUESTOS PREFERIDOS: N-[4-CLORO-3-(1,5-DIMETIL-1H-IMIDAZOL-2-IL)FENIL]-2-METIL-6-(TRIFLUOROMETIL)PIRIDIN-3-CARBOXAMIDA, N-[4-CLORO-3-(1-METIL-1H-IMIDAZOL-2-IL)FENIL]-2-METIL-6-(TRIFLUOROMETIL)PIRIDIN-3-CARBOXAMIDA, N-[3-(5-AMINOPIRAZIN-2-IL)-4-CLOROFENIL]-2-METIL-6-(TRIFLUOROMETIL)PIRIDIN-3-CARBOXAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA VIA HEDGEHOG Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS CELULARESREFERRING TO A HETEROCYCLIC DERIVATIVE COMPOUND OF FORMULA (I), WHERE R1, R2 AND R3 ARE H, HALOGEN OR C1-C6 ALKYL; R4 IS HALOGEN, C1-C6 ALKYL OR C1-C6 HALOALKYL; W IS N, O, S, CR5, AMONG OTHERS; R5 IS H, C1-C6 ALCOXYL, C1-C6 ALKYL, AMONG OTHERS; A IS N, CR6, NR6, N, O, S; R6 IS H, C1-C6 ALCOXYL, AMINO, AMIDO, AMONG OTHERS; q AND p ARE 0 OR 1. THE PREFERRED COMPOUNDS ARE: N- [4-CHLORO-3- (1,5-DIMETHYL-1H-IMIDAZOL-2-IL) PHENYL] -2-METHYL-6- (TRIFLUOROMETHYL) PYRIDIN- 3-CARBOXAMIDE, N- [4-CHLORO-3- (1-METHYL-1H-IMIDAZOL-2-IL) PHENYL] -2-METHYL-6- (TRIFLUOROMETHYL) PYRIDIN-3-CARBOXAMIDE, N- [3- ( 5-AMINOPYRAZIN-2-IL) -4-CHLOROPHENYL] -2-METHYL-6- (TRIFLUOROMETHYL) PYRIDIN-3-CARBOXAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE INHIBITORS OF THE HEDGEHOG PATHWAY AND ARE USEFUL IN THE TREATMENT OF PROLIFERATIVE CELLULAR DISEASES

PE2008001563A 2007-09-05 2008-09-05 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF THE HEDGEHOG PATH PE20091092A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97010707P 2007-09-05 2007-09-05
US3666108P 2008-03-14 2008-03-14

Publications (1)

Publication Number Publication Date
PE20091092A1 true PE20091092A1 (en) 2009-08-27

Family

ID=39938463

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001563A PE20091092A1 (en) 2007-09-05 2008-09-05 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF THE HEDGEHOG PATH

Country Status (5)

Country Link
AR (1) AR068376A1 (en)
PE (1) PE20091092A1 (en)
TW (1) TW200916458A (en)
UY (1) UY31322A1 (en)
WO (1) WO2009030952A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010144586A1 (en) * 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
JP2013516480A (en) * 2010-01-07 2013-05-13 セレクサゲン セラピューティクス，インク． Hedgehog inhibitor
WO2011095807A1 (en) * 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors
CN101993415B (en) * 2010-09-15 2013-08-14 北京韩美药品有限公司 Compound as Hedgehog path inhibitor, medicine composition containing same and application thereof
CN103570625A (en) * 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-aryl-heteroaryl)-4-aryl-aryl carboxamide and analog as hedgehog pathway inhibitors and application thereof
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (en) 2014-09-12 2016-04-29 Novartis Ag COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
WO2018082587A1 (en) * 2016-11-04 2018-05-11 上海瑛派药业有限公司 Application of hedgehog pathway inhibitor for treatment of fibrotic diseases
JP7309614B2 (en) 2017-05-02 2023-07-18 ノバルティス アーゲー combination therapy
CN107281214A (en) * 2017-06-06 2017-10-24 北京工业大学 Hydrogen molecule liquid/gas is preparing the application in suppressing tumor stem cell medicine
CN109369634B (en) * 2018-12-19 2021-07-27 陕西国际商贸学院 Preparation method and application of 2-methoxynicotinamide derivative with antitumor activity
AU2022295990A1 (en) 2021-06-18 2024-01-04 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE485275T1 (en) * 2002-02-12 2010-11-15 Glaxosmithkline Llc NICOTINAMIDES AND THEIR USE AS P38 INHIBITORS
EP1496905B1 (en) * 2002-04-22 2008-08-13 Johns Hopkins University School of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
US8273743B2 (en) * 2004-04-30 2012-09-25 Curis, Inc. Quinoxaline inhibitors of the hedgehog signalling
KR20140048343A (en) * 2004-09-02 2014-04-23 제넨테크, 인크. Pyridyl inhibitors of hedgehog signalling
WO2006050506A1 (en) * 2004-11-03 2006-05-11 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
JP2009511559A (en) * 2005-10-12 2009-03-19 バイオリポックス エービー Benzoxazoles useful for the treatment of inflammation
PE20080948A1 (en) * 2006-07-25 2008-09-10 Irm Llc IMIDAZOLE DERIVATIVES AS MODULATORS OF THE HEDGEHOG PATH

Also Published As

Publication number Publication date
AR068376A1 (en) 2009-11-11
TW200916458A (en) 2009-04-16
UY31322A1 (en) 2009-04-30
WO2009030952A2 (en) 2009-03-12
WO2009030952A3 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
PE20091092A1 (en) HETEROCYCLIC COMPOUNDS AS INHIBITORS OF THE HEDGEHOG PATH
PE20090641A1 (en) HETERO CYCLIC AMIDES
ECSP066886A (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF DISLIPIDEMIA
EA201290255A1 (en) METHODS AND COMPOSITIONS FOR CANCER TREATMENT
PE20070602A1 (en) CARBOXIAMINE COMPOUNDS AS HISTONE DESACETILASE MODULATORS
PE20090434A1 (en) SULFONIL AMIDE DERIVATIVES AS KINASE INHIBITORS
ECSP067098A (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF DISLIPIDEMIA
EA200601747A1 (en) THREE (CYCLO) SUBSTITUTED AMIDA COMPOUNDS
PE20090694A1 (en) SIRTUIN MODULATING COMPOUNDS
PE20090601A1 (en) PYRIDIN-IL-OXY-PYRIDINES DERIVATIVES AS ALK5 INHIBITORS
EA200700099A1 (en) PYRIDINE DERIVATIVES
PE20061150A1 (en) DERIVATIVES OF N- (N-SULFONYLAMINOARILMETIL) CYCLOPROPANOCARBOXAMIDE SUBSTITUTED AS ANTAGONISTS OF THE VAINILLOID RECEPTOR TYPE 1 (VDR1)
EA200870193A1 (en) CYTOTOXIC AGENTS, INCLUDING NEW TOMAMYCIN DERIVATIVES, AND THEIR THERAPEUTIC APPLICATION
PE20080906A1 (en) HETEROARYL DERIVATIVES AS CYTOKINE INHIBITORS
PE20090423A1 (en) SIRTUIN MODULATING COMPOUNDS
PE20060777A1 (en) INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
PE20121506A1 (en) TRIAZOLOPYRIDINE COMPOUNDS AS C-MET INHIBITORS
PE20070136A1 (en) COMPOUNDS DERIVED FROM N- (PYRIDIN-2-IL) -SULFONAMIDE AS INHIBITORS OF THE ENZYME 11-beta-HYDROXIESTEROID DEHIDROGENASE HUMAN TYPE 1
AR053554A1 (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
PE20091573A1 (en) HETEROCYCLIC DERIVATIVES OF UREA AS INHIBITORS OF DNA GIRASE AND / OR TOPOISOMERASE
PE20061124A1 (en) COMPOUNDS AND DERIVATIVES OF DIBENCIL AMINE
PE20140471A1 (en) MODULATORS OF THE COMPLEMENT ROUTE AND USES OF THEM
CY1108908T1 (en) KINOLINONINE - CARBOXAMIDIS COMPOUNDS AS 5-HT4 RECEPTOR AGONS
EA201000702A1 (en) SOME DERIVATIVES 2-PYRAZINONE AND THEIR APPLICATION AS NEUTROFIL ELASTASIS INHIBITORS
PE20090884A1 (en) INDOL COMPOUNDS AS GLUCOKINASE ACTIVATORS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal